Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
You may also be interested in...
Following delays due to FDA safety concerns, Novartis is moving forward with Phase III trials of its oral multiple sclerosis therapy FTY720, although one of the two doses being evaluated lacks clinical data to support its efficacy
Amgen will re-launch enrollment of head-to-head Phase II studies for its oncologic AMG 706 after concerns were raised about the potential development of cholecystitis, although the Phase III trials remain indefinitely delayed
Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters